- Home
- PMAX vs CRIS Comparison
PMAX vs CRIS Comparison
Compare PMAX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- CRIS
- Stock Information
- Founded
- PMAX 2019
- CRIS 2000
- Country
- PMAX Hong Kong
- CRIS United States
- Employees
- PMAX N/A
- CRIS N/A
- Industry
- PMAX
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMAX
- CRIS Health Care
- Exchange
- PMAX Nasdaq
- CRIS Nasdaq
- Market Cap
- PMAX 6.6M
- CRIS 32.8M
- IPO Year
- PMAX 2024
- CRIS 2000
- Fundamental
- Price
- PMAX $0.28
- CRIS $2.84
- Analyst Decision
- PMAX
- CRIS Strong Buy
- Analyst Count
- PMAX 0
- CRIS 3
- Target Price
- PMAX N/A
- CRIS $23.00
- AVG Volume (30 Days)
- PMAX 7.7M
- CRIS 28.2K
- Earning Date
- PMAX 03-25-2025
- CRIS 05-06-2025
- Dividend Yield
- PMAX N/A
- CRIS N/A
- EPS Growth
- PMAX N/A
- CRIS N/A
- EPS
- PMAX 0.04
- CRIS N/A
- Revenue
- PMAX $5,970,263.00
- CRIS $10,259,000.00
- Revenue This Year
- PMAX N/A
- CRIS N/A
- Revenue Next Year
- PMAX N/A
- CRIS N/A
- P/E Ratio
- PMAX $7.01
- CRIS N/A
- Revenue Growth
- PMAX 30.05
- CRIS 0.44
- 52 Week Low
- PMAX $0.28
- CRIS $2.57
- 52 Week High
- PMAX $4.70
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- CRIS 41.65
- Support Level
- PMAX N/A
- CRIS $2.57
- Resistance Level
- PMAX N/A
- CRIS $3.15
- Average True Range (ATR)
- PMAX 0.00
- CRIS 0.17
- MACD
- PMAX 0.00
- CRIS -0.02
- Stochastic Oscillator
- PMAX 0.00
- CRIS 44.26
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.